Lyra Therapeutics, Inc. (LYRA) confirmed earnings release on August 24, 2026, for the quarter ending June 30, 2026.The estimated EPS is $-1.54The estimated revenue is $99500 Price Impact of Stock Earnings Earnings Surprise Potential: If the actual earnings exceed market expectations, it could trigger a positive response from investors, leading to buying activity and a...
Yiren Digital Ltd. (YRD) confirmed earnings release on August 24, 2026, Before the market for the...
Kandi Technologies Group, Inc. (KNDI) confirmed earnings release on August 24, 2026, Before the market for...
Mondee Holdings, Inc. (MOND) confirmed earnings release on August 24, 2026, for the quarter ending March...
Sotherly Hotels Inc. (SOHON) confirmed earnings release on August 24, 2026, for the quarter ending June...
from Craig-Hallum issued a price target of $16.25 for PSNL on 2026-08-24 12:55:17.The adjusted price target was set to $16.25.At the time of the announcement, PSNL was trading at $17.22.The...
from Barrington issued a price target of $14.00 for VMD on 2026-08-24 11:33:30.The adjusted price target was set to $14.00.At the time of the announcement, VMD was trading at $8.85.VMD...
Martin Auster from Raymond James issued a price target of $18.00 for STTK on 2026-08-24 10:06:00.The adjusted price target was set to $18.00.At the time of the announcement, STTK was...
from Goldman Sachs issued a price target of $20.00 for AEVA on 2026-08-24 00:20:28.The adjusted price target was set to $20.00.At the time of the announcement, AEVA was trading at...
Danielle Brill from Truist Financial issued a price target of $20.00 for SLDB on 2026-08-21 11:27:42.The adjusted price target was set to $20.00.At the time of the announcement, SLDB was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
